AHFS February 2022 Update

This update contains 7 new monographs and 43 revised monographs.

New monographs: Efgartigimod Alfa-Fcab; Maribavir; Molnupiravir; Nirmatrelvir And Ritonavir; Tezepelumab; Tixagevimab And Cilgavimab; Vosoritide.

Revised monographs: Atorvastatin; Bamlanivimab and Etesevimab; Bivalirudin; Cangrelor; Casirivimab and Imdevimab; Clopidogrel; Cobimetinib; COVID-19 Vaccine (Janssen); COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Dexmethylphenidate/Serdexmethylphenidate; Diclofenac; Dimethyl Fumarate; Diroximel Fumarate; Entrectinib; Factor Xa (recombinant), Inactivated-zhzo; Fedratinib; Fluvastatin; Glasdegib; HMG-CoA Reductase Inhibitors General Statement; Hyperosmotic Laxatives; idaruCIZUmab; Iloperidone; Imipenem and Cilastatin; Ivosidenib; Lenvatinib; Loncastuximab; Lovastatin; Meningococcal Groups A, C, Y, and W-135 Vaccine; Methylphenidate; Monomethyl Fumarate; Palbociclib; Pitavastatin; Pravastatin; Prothrombin Complex Concentrate; Remdesivir; Rosuvastatin; Selpercatinib; Simvastatin; Sotrovimab; Sucroferric Oxyhydroxide; Sugammadex; Ursodiol